Serum Institute seeks DCGI nod to examine and manufacture Sputnik V in India

The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June
Image for representational purpose only (Pic: Reuters)
Image for representational purpose only (Pic: Reuters)

The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission for a test license to manufacture COVID-19 vaccine Sputnik V in the country, sources said on Thursday. The Pune-based firm has also sought a test license for analysis and examination. Russia's Sputnik V vaccine is currently being manufactured in India by Dr Reddy's Laboratories.

"The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission for a test license to manufacture the COVID-19 vaccine, Sputnik V, in India," a source said.

The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June, while it is also manufacturing the Novavax vaccine, the regulatory clearance for which is awaited from the United States. The vaccine was given emergency use authorisation (EUA) by the DCGI in April. A consignment of 30 lakh doses of Sputnik V landed in Hyderabad on Tuesday.

Related Stories

No stories found.
X
logo
EdexLive
www.edexlive.com